Free Trial

STERIS (STE) Stock Forecast & Price Target

STERIS logo
$245.04 +1.65 (+0.68%)
Closing price 09/5/2025 03:59 PM Eastern
Extended Trading
$244.49 -0.55 (-0.23%)
As of 09/5/2025 06:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

STERIS - Analysts' Recommendations and Stock Price Forecast (2025)

Consensus Rating

Sell
0
Hold
2
Buy
6

Based on 8 Wall Street analysts who have issued ratings for STERIS in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 8 analysts, 2 have given a hold rating, and 6 have given a buy rating for STE.

Consensus Price Target

$273.50
11.61% Upside
According to the 8 analysts' twelve-month price targets for STERIS, the average price target is $273.50. The highest price target for STE is $295.00, while the lowest price target for STE is $250.00. The average price target represents a forecasted upside of 11.61% from the current price of $245.04.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for STE and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for STERIS and its competitors.

Sign Up
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

STE Analyst Ratings Over Time

TypeCurrent Forecast
9/7/24 to 9/7/25
1 Month Ago
8/8/24 to 8/8/25
3 Months Ago
6/9/24 to 6/9/25
1 Year Ago
9/8/23 to 9/7/24
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
6 Buy rating(s)
6 Buy rating(s)
5 Buy rating(s)
3 Buy rating(s)
Hold
2 Hold rating(s)
2 Hold rating(s)
3 Hold rating(s)
3 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$273.50$273.50$263.83$246.00
Forecasted Upside11.61% Upside12.52% Upside8.72% Upside2.58% Upside
Consensus RatingModerate BuyModerate BuyModerate BuyModerate Buy

STE Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

STE Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

STERIS Stock vs. The Competition

TypeSTERISMedical CompaniesS&P 500
Consensus Rating Score
2.75
2.78
2.53
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside11.61% Upside16,047.34% Upside10.35% Upside
News Sentiment Rating
Positive News

See Recent STE News
Positive News
Positive News
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside
Details
8/8/2025Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Patrick Wood
Not Rated
Boost TargetOverweight$276.00 ➝ $295.00+22.18%
7/22/2025KeyCorp
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Brett Fishbin
Not Rated
Boost TargetOverweight$277.00 ➝ $288.00+28.78%
5/29/2025Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
David Windley
Not Rated
Initiated CoverageHold$263.00+7.33%
5/16/2025Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Reiterated RatingOutperform
5/16/2025JMP Securities
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetMarket Outperform$265.00 ➝ $280.00+11.84%
5/15/2025Stephens
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweight$250.00 ➝ $250.00+1.92%
4/7/2025Needham & Company LLC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingHold
2/3/2025Piper Sandler
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetOverweight$260.00 ➝ $265.00+21.26%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 10:54 PM ET.


Should I Buy STERIS Stock? STE Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, September 3, 2025. Please send any questions or comments about these STERIS pros and cons to contact@marketbeat.com.

STERIS
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in STERIS plc:

  • The current stock price is around $273.50, reflecting a positive outlook from analysts who have rated the stock with a consensus of "Moderate Buy."
  • STERIS plc recently reported quarterly earnings that exceeded expectations, with a revenue increase of 8.8% compared to the same quarter last year, indicating strong business growth.
  • The company has a solid net margin of 11.61% and a return on equity of 14.17%, showcasing effective management and profitability.
  • STERIS plc has increased its quarterly dividend to $0.63, which represents a yield of 1.0%. This increase signals confidence in future earnings and provides a return to shareholders.
  • Recent upgrades from multiple analysts, including a boost in price targets, suggest that market sentiment is favorable and that the stock may continue to appreciate.

STERIS
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in STERIS plc for these reasons:

  • Insider selling has occurred, with a total of 36,335 shares sold recently, which may indicate a lack of confidence from those closest to the company.
  • Despite positive earnings, the stock's performance may be affected by broader market conditions, which can lead to volatility.
  • The company operates in a competitive sector, and any changes in regulations or market dynamics could impact its profitability.
  • While the dividend has increased, the payout ratio is 34.92%, which may limit future dividend growth if earnings do not continue to rise.
  • Analysts have mixed ratings, with some holding a "hold" position, suggesting that not all market participants are convinced of the stock's potential for growth.

STE Forecast - Frequently Asked Questions

According to the research reports of 8 Wall Street equities research analysts, the average twelve-month stock price forecast for STERIS is $273.50, with a high forecast of $295.00 and a low forecast of $250.00.

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for STERIS in the last year. There are currently 2 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" STE shares.

According to analysts, STERIS's stock has a predicted upside of 11.61% based on their 12-month stock forecasts.

Over the previous 90 days, STERIS's stock had 1 upgrade by analysts.

STERIS has been rated by research analysts at KeyCorp, and Morgan Stanley in the past 90 days.

Analysts like STERIS less than other "medical" companies. The consensus rating score for STERIS is 2.75 while the average consensus rating score for "medical" companies is 2.78. Learn more on how STE compares to other companies.


This page (NYSE:STE) was last updated on 9/7/2025 by MarketBeat.com Staff
From Our Partners